A Phase 1b/2, Open-label Clinical Study to Determine Preliminary Safety and Efficacy of Alvocidib When Administered in Sequence After Decitabine in Patients with MDS
Study of Alvocidib When Administered in Sequence After Decitabine in Patients with Myeolodysplastic Syndromes (MDS)
Sponsor: Tolero Pharmaceuticals
Enrolling: Male and Female Patients
IRB Number: AAAR9983
U.S. Govt. ID: NCT03593915
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this research study is to determine the preliminary safety and effectiveness (how well something works) of alvocidib when used after the standard drug decitabine in patients with MDS. The study will also gain information about the PK (the process by which a drug is absorbed, distributed, metabolized and eventually eliminated by the body), pharmacodynamic (PD) biomarkers (which study how the drug effects the body) and other biomarkers that may help understand more about how your disease responds to the drug.
This study is closed
Investigator
Daniel Lee, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Have you been previously treated for Myelodysplastic Syndromes (MDS)? Yes No
Are you willing to comply with the requirements of the entire study? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162